Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Down 15.0% in November

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 39,700 shares, a drop of 15.0% from the October 31st total of 46,700 shares. Based on an average trading volume of 23,700 shares, the days-to-cover ratio is presently 1.7 days. Currently, 1.4% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Kiora Pharmaceuticals in a research report on Tuesday, November 12th.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises about 0.8% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals as of its most recent SEC filing. 76.97% of the stock is currently owned by institutional investors.

Kiora Pharmaceuticals Price Performance

Kiora Pharmaceuticals stock traded up $0.28 during midday trading on Monday, hitting $3.54. 30,436 shares of the company’s stock were exchanged, compared to its average volume of 71,417. The stock has a 50-day moving average price of $3.48 and a two-hundred day moving average price of $4.18. Kiora Pharmaceuticals has a 52-week low of $3.00 and a 52-week high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. On average, research analysts forecast that Kiora Pharmaceuticals will post 0.89 earnings per share for the current fiscal year.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.